An open-label, nonrandomized, phase Ib feasibility study of cusatuzumab in patients with nasopharyngeal carcinoma.
De Meulenaere A, Vermassen T, Creytens D, De Keukeleire S, Delahaye T, Deron P, Duprez F, Fung S, Pauwels P, Ferdinande L, Rottey S.
De Meulenaere A, et al. Among authors: de keukeleire s.
Clin Transl Sci. 2021 Nov;14(6):2300-2313. doi: 10.1111/cts.13089. Epub 2021 Oct 27.
Clin Transl Sci. 2021.
PMID: 34405542
Free PMC article.
Clinical Trial.
An infusion-related reaction was observed in two of 11 patients. Laboratory results showed no trend over time. Seven patients were eligible for response evaluation. No objective response to cusatuzumab was observed with stable disease being the best response. ...
An infusion-related reaction was observed in two of 11 patients. Laboratory results showed no trend over time. Seven patients were el …